- Molecular NameTeicoplanin_A2-1
- SynonymNA
- Weight1877.66
- Drugbank_IDDB06149
- ACS_NO91032-34-7
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)N/A
- pkaN/A
- LogD (pH=7, predicted)N/A
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)N/A
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond DonorsN/A
- No.of HBond AcceptorsN/A
- No.of Rotatable BondsN/A
- TPSAN/A
- StatusFDA approved
- AdministrationN/A
- PharmacologyN/A
- Absorption_value0.0
- Absorption (description)Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly.
- Caco_2N/A
- Bioavailability0.0
- Protein binding92.5
- Volume of distribution (VD)0.9~1.6 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmTwo metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) have been isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were found to be new teicoplanin-like molecules, bearing 8-hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the omega-2 and omega-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.
- Half life30 to over 160 h in normal subjects (depending on the sampling time), increased in renal impairment; an effective half-life of about 60 h has been suggested in calculating dosage regimens.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A